International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol

Participation in this study will require 5 study visits over 2-4 weeks.

- Visit 1: screening/enrollment visit to assess study eligibility.

- Visit 2: continuous glucose monitor (CGM) training and initiation session based upon
current or prior use of a CGM; if subject doesn't currently use a CGM, subject will be
trained and may be asked to wear the CGM at home for 1 week.

- Visit 3: subjects will be taught how to use the study insulin pump.

- Visit 4: subjects will be trained on the use of inControl and wear it at home for 14
days.

- Visit 5: subjects will return study equipment and to complete questionnaire.

Inclusion Criteria

1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
one year and using insulin for at least 1 year

2. Use of an insulin pump for at least 6 months with established parameters for basal
rate(s), carbohydrate ratio(s) and insulin sensitivity factor(s) for at least 3
months.

3. Age 14.0 to <75.0 years

4. HbA1c level <10.5% at screening

5. For females, not currently known to be pregnant. If female and sexually active, must
agree to use a form of contraception to prevent pregnancy while a participant in the
study. A negative serum or urine pregnancy test will be required for all premenopausal
women who are not surgically sterile. Subjects who become pregnant will be
discontinued from the study. Also, subjects who during the study develop and express
the intention to become pregnant within the timespan of the study will be
discontinued.

6. Have care partner committed to participating in all training activities, knowledgeable
at all times of the participants location, and being present and available to provide
assistance when the system is being used at night

7. Willingness, if using the closed-loop system, to stop closed-loop when taking
acetaminophen and avoid closed-loop for at least 4 hours afterward

8. Willingness to suspend use of any personal CGM for the duration of the clinical trial
once the study CGM is in use

9. Willingness to establish network connectivity on a daily basis either via local Wi-Fi
network or via a study-provided cellular service

10. Investigator has confidence that the subject can successfully operate all study
devices and is capable of adhering to the protocol

11. Currently using no insulins other than one of the following rapid-acting insulins at
the time of enrollment: insulin lispro (Humalog), insulin aspart (Novolog), or insulin
glulisine (Apidra)

12. Total daily insulin dose (TDD) less than 100 U/day

Exclusion Criteria

1. More than one episode of diabetic ketoacidosis (DKA) in the 6 months prior to
enrollment

2. More than one episode of severe hypoglycemia involving seizure of loss of
consciousness in the 6 months prior to enrollment

3. Medical need for chronic acetaminophen

4. Concurrent use of any non-insulin glucose-lowering agent (including GLP-1 agonists,
Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, biguanides, sulfonylureas and
naturaceuticals).

5. Hemophilia or any other bleeding disorder

6. A condition, which in the opinion of the investigator or designee, would put the
participant or study at risk

7. Participation in another pharmaceutical or device trial at the time of enrollment or
during the study

8. Employed by, or having immediate family members employed by TypeZero Technologies, LLC